China Universal Asset Management Co. Ltd. Raises Stock Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)

China Universal Asset Management Co. Ltd. boosted its holdings in Bicycle Therapeutics plc (NASDAQ:BCYC) by 30.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 9,329 shares of the company’s stock after acquiring an additional 2,191 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Bicycle Therapeutics were worth $131,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Avior Wealth Management LLC bought a new stake in shares of Bicycle Therapeutics during the 4th quarter valued at about $57,000. JPMorgan Chase & Co. grew its stake in shares of Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after purchasing an additional 1,782 shares during the period. Principal Financial Group Inc. bought a new stake in shares of Bicycle Therapeutics during the 3rd quarter valued at about $10,028,000. Geode Capital Management LLC grew its stake in shares of Bicycle Therapeutics by 79.3% during the 3rd quarter. Geode Capital Management LLC now owns 38,335 shares of the company’s stock valued at $868,000 after purchasing an additional 16,958 shares during the period. Finally, Jane Street Group LLC grew its stake in shares of Bicycle Therapeutics by 35.7% during the 3rd quarter. Jane Street Group LLC now owns 20,180 shares of the company’s stock valued at $457,000 after purchasing an additional 5,310 shares during the period. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Stephens restated an “equal weight” rating and set a $15.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. B. Riley cut their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. HC Wainwright reiterated a “buy” rating and set a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Monday, January 13th. Finally, JMP Securities cut their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Bicycle Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.25.

Insider Buying and Selling

In related news, CAO Travis Alvin Thompson sold 2,686 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $15.00, for a total value of $40,290.00. Following the transaction, the chief accounting officer now directly owns 32,146 shares of the company’s stock, valued at approximately $482,190. The trade was a 7.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bros. Advisors Lp Baker acquired 500,000 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were purchased at an average cost of $15.34 per share, for a total transaction of $7,670,000.00. Following the completion of the acquisition, the director now directly owns 9,995,274 shares in the company, valued at approximately $153,327,503.16. This represents a 5.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 33,933 shares of company stock valued at $549,501. Corporate insiders own 8.50% of the company’s stock.

Bicycle Therapeutics Trading Down 5.5 %

NASDAQ BCYC opened at $12.66 on Tuesday. The stock’s 50 day moving average is $15.68 and its 200 day moving average is $20.82. Bicycle Therapeutics plc has a 12 month low of $12.17 and a 12 month high of $28.67. The stock has a market cap of $874.17 million, a PE ratio of -3.85 and a beta of 0.93.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.